TxCell is developing immunotherapies based on the discovery of a type of T-cells that have anti-inflammatory properties – regulatory T lymphocytes (Tregs).
Tregs have already yielded two candidates. Osave is currently on phase IIb trial for refractory Crohn’s disease, and Col-Treg has received Orphan Drug Designation to treat autoimmune uveitis, which causes blindness.
TxCell is now moving to its second technology platform with ENTrIA, which stands for ‘Engineered Treg for Inflammation and Autoimmunity‘. It creates engineered Tregs with chimeric antigen receptors (CAR) – the same strategy that yields CAR-T therapies for cancer.
The first CAR-Tregs will be developed for lupus nephritis, one of the most serious complications which affects the kidneys in lupus erythmatosus – a rare autoimmune disease with high unmet medical needs.